The Full Federal Court has handed Johnson & Johnson unit Ethicon a victory in the class action over its allegedly defective vaginal mesh devices, partly reversing a judge’s decision that expanded the class post-trial.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy’s Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.
The Public Trustee of Queensland asked a court Wednesday for indemnity costs from a global litigation funder its says was the “real moving force” behind a dismissed investor class action it called a “nakedly speculative venture”.
The bitter dispute between Gina Rinehart and two of her children over billions of dollars in iron ore mining assets may come down to how the High Court interprets a single word in an arbitration clause of agreements signed by the warring family members.
The long, complex battle over who owns the rights to the Kraft peanut butter trade dress just promised to get longer, with Kraft winning approval to bring fresh allegations against Bega mid-trial.
A group of Indigenous Australians has failed to block Adani Mining’s $16 billion development of the proposed Carmichael coal mine in central Queensland, with a judge dismissing the claims as “void of merit”.
Global pharmaceutical giant Sanofi-Aventis has launched patent infringement proceedings against generic drug maker Alphapharm seeking “urgent interlocutory relief” to prevent a generic injector pen from being listed on the market.
Plastic banknote company Securency has been ordered to pay more than $64 million after it tricked its agent in Nigeria into signing away his commission in what the Federal Court called a “shabby fraud”.
Fundraising company Appco Group Australia has failed in its bid to put a massive sham contracting class action in the Federal Court on hold while it fights a ruling that let the case continue as a representative proceeding.
Lawyers on both sides of the class action against American Medical Services over pelvic mesh implants have taken steps to ensure the case proceeds with greater efficiency than the pelvic mesh class action against Johnson & Johnson, which went to an 89-day trial five years after that case was filed.